Due to Pfizer’s underperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautious ...

Pfizer says it is standing behind its dividend, which makes the stock's 6.4% yield quite attractive.

PFE stock decreased 30.0% from a peak of $40.71 on January 23, 2020, to $28.49 on March 23, 2020, compared to a ...

The stock market can be quite turbulent. Growth stocks, while having tremendous potential, can also be risky, as we have seen this month. The once-hyped AI growth stocks plummeted as investors failed ...

Pfizer Inc. delivered a 17% total return since early November, but fundamentals lag and valuation isn’t compelling. Read more ...

Pfizer Inc. PFE shares are trending on Wednesday following the U.S. Food and Drug Administration’s (FDA) full approval of the BRAFTOVI combination regimen for treating metastatic colorectal cancer.

Historical patterns indicate that abrupt fluctuations in the market can impact any firm, regardless of its seeming dominance.

Pfizer faces multi-year headwinds from loss of exclusivity and COVID franchise decline, but management highlights transformative M&A and pipeline optionality. Learn more on PFE stock here.

Pfizer Inc. (NYSE:PFE) is included among the 14 Best Affordable Dividend Stocks to Buy According to Analysts. On February 25, ...

Pfizer's long-acting GLP-1 weight loss candidate could set the stage for a stock rally.